Upon treatment with cetuximab, an approved anti-cancer drug for head and neck squamous cell carcinoma (HNSCC), membrane-bound epidermal growth factor receptor (EGFR) and alanine-serine-cysteine transporter 2 (ASCT2) were found to interact with AP1G1, resulting in the sensitization of cancer cells to reactive oxygen species (ROS) treatment, which might contribute to a higher survival rate in the patient group showing a higher AP1G1 expression [35]. Here, SLC1A5 is linked to head and neck squamous cell carcinoma.